New Products: NanoString Technologies' nCounter PanCancer Pathways Panel | GenomeWeb

NanoString Technologies this week launched its nCounter PanCancer Pathways Panel, a highly-multiplexed, digital gene expression assay that enables translational researchers to investigate cancer biology across all major cancer pathways.

From a single tube, the PanCancer Pathways Panel simultaneously analyzes 770 genes associated with all of the key cancer pathways: PI3K, STAT, MAPK, TGFβ, Notch, Hedgehog, Wnt, apoptosis, cell cycle, RAS, chromatin modification, transcriptional regulation, and DNA damage control.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.